PHIO PHARMACEUTICALS CORP. Cash and Cash Equivalents, Period Increase (Decrease)
PHIO PHARMACEUTICALS CORP. (PHIO) reported Cash and Cash Equivalents, Period Increase (Decrease) of $7.79 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-30.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-03-30
- PHIO PHARMACEUTICALS CORP. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was $10.53M, a 872.92% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was -$1.45M.
- PHIO PHARMACEUTICALS CORP. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-06-30 was -$360.00K.
- PHIO PHARMACEUTICALS CORP. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-03-31 was -$925.00K.
- PHIO PHARMACEUTICALS CORP. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $7.79M.
- PHIO PHARMACEUTICALS CORP. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$3.38M.
- PHIO PHARMACEUTICALS CORP. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$2.89M, a 146.21% decline from fiscal 2013.
- PHIO PHARMACEUTICALS CORP. cash and cash equivalents, period increase (decrease) for fiscal 2013 was $6.26M, a 35.45% increase from fiscal 2012.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 111 month | Cash and Cash Equivalents, Period Increase (Decrease) 114 month | Cash and Cash Equivalents, Period Increase (Decrease) 117 month |
|---|---|---|---|---|---|---|---|
| 2016-12-31 | $10.53M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $9.07M derived: sum of 2 quarters · filed 2017-03-30 | $8.71M derived: sum of 3 quarters · filed 2017-03-30 | $7.79M 10-K · filed 2017-03-30 | |||
| 2016-09-30 | -$1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$1.81M derived: sum of 2 quarters · filed 2016-11-10 | -$2.74M 10-Q · filed 2016-11-10 | -$1.66M derived: sum of 4 quarters · filed 2017-03-30 | |||
| 2016-06-30 | -$360.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$1.28M 10-Q · filed 2016-08-11 | -$203.00K derived: sum of 3 quarters · filed 2017-03-30 | -$2.15M derived: sum of 4 quarters · filed 2017-03-30 | |||
| 2016-03-31 | -$925.00K 10-Q · filed 2016-05-12 | $157.00K derived: sum of 2 quarters · filed 2017-03-30 | -$1.79M derived: sum of 3 quarters · filed 2017-03-30 | -$2.39M derived: sum of 4 quarters · filed 2017-03-30 | |||
| 2015-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$869.00K derived: sum of 2 quarters · filed 2017-03-30 | -$1.46M derived: sum of 3 quarters · filed 2017-03-30 | -$3.38M 10-K · filed 2017-03-30 | |||
| 2015-09-30 | -$1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$2.54M derived: sum of 2 quarters · filed 2016-11-10 | -$4.46M 10-Q · filed 2016-11-10 | -$1.09M derived: sum of 4 quarters · filed 2016-11-10 | |||
| 2015-06-30 | -$594.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$2.51M 10-Q · filed 2016-08-11 | $856.00K derived: sum of 3 quarters · filed 2016-08-11 | -$5.92M derived: sum of 4 quarters · filed 2016-08-11 | |||
| 2015-03-31 | -$1.92M 10-Q · filed 2016-05-12 | $1.45M derived: sum of 2 quarters · filed 2016-05-12 | -$5.33M derived: sum of 3 quarters · filed 2016-05-12 | -$2.43M derived: sum of 4 quarters · filed 2016-05-12 | |||
| 2014-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$3.42M derived: sum of 2 quarters · filed 2016-03-30 | -$514.00K derived: sum of 3 quarters · filed 2016-03-30 | -$2.89M 10-K · filed 2016-03-30 | |||
| 2014-09-30 | -$6.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$3.88M derived: sum of 2 quarters · filed 2015-11-12 | -$6.26M 10-Q · filed 2015-11-12 | -$1.72M derived: sum of 4 quarters · filed 2015-11-12 | |||
| 2014-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $521.00K 10-Q · filed 2015-08-12 | $5.06M derived: sum of 3 quarters · filed 2015-08-12 | $3.32M derived: sum of 4 quarters · filed 2015-08-12 | |||
| 2014-03-31 | -$2.38M 10-Q · filed 2015-05-13 | $2.16M derived: sum of 2 quarters · filed 2015-05-13 | $423.00K derived: sum of 3 quarters · filed 2015-05-13 | -$10.63M derived: sum of 4 quarters · filed 2015-05-13 | |||
| 2013-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $2.80M derived: sum of 2 quarters · filed 2015-03-30 | -$8.25M derived: sum of 3 quarters · filed 2015-03-30 | $6.26M 10-K · filed 2015-03-30 | |||
| 2013-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$12.80M derived: sum of 2 quarters · filed 2014-11-13 | $1.72M 10-Q · filed 2014-11-13 | $569.00K derived: sum of 4 quarters · filed 2014-11-13 | |||
| 2013-06-30 | -$11.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $3.46M 10-Q · filed 2014-08-14 | $2.31M derived: sum of 3 quarters · filed 2014-08-14 | $1.06M derived: sum of 4 quarters · filed 2014-08-14 | |||
| 2013-03-31 | $14.52M 10-Q · filed 2014-05-14 | $13.37M derived: sum of 2 quarters · filed 2014-05-14 | $12.12M derived: sum of 3 quarters · filed 2014-05-14 | $19.34M derived: sum of 4 quarters · filed 2014-05-14 | |||
| 2012-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | -$2.40M derived: sum of 2 quarters · filed 2014-03-28 | $4.82M derived: sum of 3 quarters · filed 2014-03-28 | $4.62M 10-K · filed 2014-03-28 | |||
| 2012-09-30 | -$1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $5.97M derived: sum of 2 quarters · filed 2013-11-14 | $5.78M 10-Q · filed 2013-11-14 | $6.28M 10-Q · filed 2012-11-13 | |||
| 2012-06-30 | $7.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $7.02M 10-Q · filed 2013-08-14 | $7.58M 10-Q · filed 2012-08-14 | ||||
| 2012-03-31 | -$199.00K 10-Q · filed 2013-05-15 | $357.00K 10-Q · filed 2012-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |